Boston Scientific stock gains pipeline support after Q3 report
Published on 10/30/2026 at 16:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline Progress Meets Near-Term Pressure
- Boston Scientific began enrollment in the Elite AF trial for its next-generation WATCHMAN Elite device.
- FDA clearances expanded the StoneSmart and SEISMIQ product portfolios.
- Management expects fourth-quarter sales to decline as the cybersecurity disruption continues to affect operations.
Boston Scientific added several pipeline milestones to its third-quarter update on Wednesday, October 28, 2026, while setting a weaker near-term sales outlook. In its third-quarter results release, the medical technology company said it had begun enrollment in the Elite AF clinical trial for the next-generation WATCHMAN Elite left atrial appendage closure device.
New Devices Expand The Pipeline
The trial will assess the device in patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy and seek a non-pharmacological alternative. Boston Scientific also received US Food and Drug Administration 510(k) clearance for the Navigator Flex Ureteral Access Sheath Set and the LithoVue Elite single-use digital flexible ureteroscope with temperature sensing.
The company received a further FDA clearance for an expanded size range of its SEISMIQ intravascular lithotripsy peripheral catheter. It also highlighted a collaboration with Heartflow to advance artificial-intelligence-supported computed tomography planning for percutaneous coronary intervention.
Guidance Signals A Difficult Finish
Third-quarter net sales reached USD 5.138 billion, up 1.5 percent from the year-earlier period on reported, operational and organic bases. Adjusted earnings per share was USD 0.73, while GAAP earnings per share was USD 0.40, compared with USD 0.51 a year earlier.
Management now expects fourth-quarter reported and organic sales to decline between 1.0 percent and 3.0 percent year over year. Full-year 2026 reported sales growth is forecast at 4.25 percent and organic growth at 3.75 percent, with adjusted earnings per share of USD 3.16 to USD 3.18.
The real-time quote of Boston Scientific stock was 38.40 euros on Lang & Schwarz at 4:02 p.m. Berlin time on Friday, October 30, 2026.
Boston Scientific Corporation
- ISIN: US1011371077
- NYSE ticker: BSX
- Latest Lang & Schwarz quote: 38.40 euros, October 30, 2026, 4:02 p.m. Berlin time
- Third-quarter net sales: USD 5.138 billion
- Third-quarter organic sales growth: 1.5 percent
- Full-year 2026 organic sales guidance: 3.75 percent
The S&P 500 remains the relevant broad-market reference for US-listed medical technology shares.
